Johnson & Johnson is trying to make a vaccine that will work in populations around the world that are infected with myriad strains of the rapidly changing virus.
Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, cautioned: “There’s always excitement, but it should be saved for the results.”
J&J is trying to make a vaccine that will work in populations around the world that are infected with myriad strains of the rapidly changing virus. Other candidate shots have focused on preventing single varieties. The World Health Organization has set a goal of cutting global HIV-related deaths to less than half a million by next year, and a vaccine is seen as a crucial tool to help
Along with the diversity of strains, HIV presents a number of obstacles to vaccination. Reservoirs of the virus can accumulate within certain cells, undetected by the immune system. No one has been able to fashion a vaccine that brings forth broadly neutralizing antibodies, the body’s most effective protection against viruses. Still, the J&J vaccine has provided protection in up to two-thirds of tested animals and has so far proved safe in humans, Barouch said.
“You’ve got this picture where there’s one study in women at risk and another about to start in men,” he said. “You can put the trials together in one overall submission to regulators.”
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Use of HIV prevention pill, PrEP, rises 500%, report saysUse of a daily pill to prevent HIV infection spiked almost 500% over three years, according to new research released today by the US Centers for Disease Control and Prevention. Over a third of those at risk of HIV infection are now protected with the medication, which is more than 90% effective, according to the CDC.
Read more »
Stocks making the biggest moves midday: Johnson & Johnson, Stitch Fix, Illumina, Merck & moreThese are the stocks posting the largest moves in midday trading.
Read more »